Rating Change
UBS reiterated its Buy rating on GRAIL, Inc. (NASDAQ:GRAL) on October 02, 2026.
UBS reiterated its Buy rating on GRAIL, Inc. (NASDAQ:GRAL) on October 02, 2026.

At publication ·
GRAIL, Inc. (NASDAQ:GRAL) · reiterate
At a glance
UBS reiterated its Buy rating on GRAIL, Inc. (NASDAQ:GRAL) on October 02, 2026.
GRAIL, Inc. operates in the Healthcare sector. The stock currently trades at $152.28 with a market capitalization of $3.3B.
Analyst coverage from UBS provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for GRAIL, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 5 Buy, 5 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 02, 2026 | UBS | Buy | N/A |
| Oct 01, 2026 | Guggenheim | Buy | N/A |
| Sep 28, 2026 | Canaccord Genuity | Buy | N/A |
| Sep 25, 2026 | Mizuho | Neutral | N/A |
| Sep 22, 2026 | Baird | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View GRAL Stock Page
A rating of Buy from UBS reflects the analyst's outlook on GRAIL, Inc. (NASDAQ:GRAL). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the GRAL forecast page.
Current market data
NASDAQ · GRAL
$128.78
Down: -$4.12 · -3.10%
Live quote updated
Keep reading